Loading company…
Nanjing Kati Medical Technology, known as CART, is a Nanjing, China-based company developing CAR-T cell therapy for solid tumors.
Based in Nanjing, China and established in 2017, Nanjing Kati Medical Technology develops solid tumor CAR-T cell therapy and immune cell therapy. The company set up its CMP platform in July 2017 and started its first clinical trial for patients with solid tumors in 2018. Its research areas include DAP12 platform based CAR pipelines, CAR signal platforms based on natural T cell receptors, CAR and TCR-T, lentivirus vectors, and CAR-T manufacturing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in